



**A Letter from the Founder,
Dr. Christine Brezden-Masley**

Dear CCTC members,

Once again, thank you for supporting the CCTC. We look forward to providing you up-to-date clinical trials information that is seamless and fast. By increasing our provincial clinical trials enrollment, this has the potential to benefit patients and allow for more clinical trials to be considered in Canada.

If you have any concerns or improvements of the website, please let us know. Be sure to follow our twitter page [@COMET_Trials](#) for the latest updates regarding open trials.

Sincerely,

Dr. Christine Brezden-Masley

**A Letter from the Project Manager,
Daniel Lindsay**

Hello everyone,

Please feel free to share this newsletter with any colleagues that may be interested, as we are always happy to have new members join our network! Please contact me at cometrials@smh.ca for any questions or comments.

Kind Regards,

Daniel Lindsay

ARTICLE RECOMMENDATION

Understanding and addressing the lack of clinical trial enrollment among adolescents with cancer.

Tai E., Buchanan N., Eliman D., Westervelt L., Beaupin L., Lawvere S., Bleyer A.

DOI: [10.1542/peds.2014-0122D](https://doi.org/10.1542/peds.2014-0122D) Published June 2014

ABSTRACT:

Despite overall improvement in survival, morbidity, and quality of life of US patients with cancer, this progress is less prevalent in the population of adolescent and young adult patients with cancer, including those between the ages of 15 and 19 years. Evidence suggests that participation in clinical trials is associated with better survival outcomes among children and adolescents with cancer; however, adolescents have lower clinical trial participation rates compared with younger age cohorts. To better understand the unique concerns among adolescent patients with cancer, the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention convened a workgroup of researchers and health care providers in the field of adolescent and young adult oncology and cancer survivorship to examine the barriers and challenges limiting the participation of adolescents in clinical trials and to define ways to improve upon these concerns. This article summarizes the activities of the workgroup and their suggestions for enhanced accrual.

TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	GI	GU	GYNE	Head & Neck	Heme	Lung	Mel	Skin	Total
Imaging Study		1		2			1				4
Observational	1	4	1	1			1				8
Prevention		1	1				1				3
Radiation	1	2	3	5		1		5			17
Supportive Care	1	4									5
Surgical Therapy		1		1	1	1					4
Systemic Therapy	4	9	17	15	6	3	15	8	3	1	81
Therapeutic				2			2				4
TOTAL	7	22	22	26	7	5	20	13	3	1	126



TRIALS OF THE MONTH


Type	Acronym	Study Title	Description	Site(s)
Breast	POLARIS	Palbociclib In Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-interventional Study	<ul style="list-style-type: none"> • Non-interventional Study • HR+/HER2- 	St. Michael's Hospital
GU	PETMUSE	Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging	<ul style="list-style-type: none"> • Urothelial Carcinoma • Imaging Study 	Odette Cancer Centre
Heme	MOR208C204	A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)	<ul style="list-style-type: none"> • Diffuse Large B-Cell Lymphoma • Systemic Therapy 	Kingston General Hospital
Lung	ALMERA	A Phase II Study to Investigate a Combination of Metformin With Chemo-Radiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer	<ul style="list-style-type: none"> • Non-small Cell Lung Cancer • Non-metastatic 	Grand River Hospital
GYNE	Empower	An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma	<ul style="list-style-type: none"> • Metastatic Cervical Cancer • Systemic Therapy 	London Health Sciences Centre
GI	HALO-109-301	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	<ul style="list-style-type: none"> • Metastatic Pancreatic Cancer • Systemic Therapy 	Royal Victoria Regional Health Centre





MEMBERSHIP UPDATES

282 members
29 institutions
126 accruing trials



ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8

cometrials@smh.ca
(416) 809-3915

@COMET_Trials
www.cometrials.com

INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	3
Grand River Hospital	Waterloo	7	1
Humber River Regional Hospital	Toronto	5	2
Kingston General Hospital	Kingston	3	36
Juravinski Cancer Centre	Hamilton	6	-
Lakeridge Health Corporation	Oshawa	20	-
London Health Sciences Centre	London	10	54
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	-
Mount Sinai Hospital	Toronto	2	1
North York General Hospital	Toronto	13	5
Odette Cancer Centre/Sunnybrook	Toronto	64	52
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	24	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	23	14
Scarborough General Hospital	Toronto	3	-
Southlake Regional Health Centre	Newmarket	20	6
St. Joseph's Health Centre	Toronto	3	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	13	7
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Trillium Health Partners	Mississauga	18	2
William Osler Health Systems	Brampton	3	-
Windsor Regional Hospital	Windsor	2	-